ライフサイエンスコーパス: disoproxil

1 e increases than those given E/C/F/tenofovir disoproxil fumarate (0.08 vs 0.12 mg/dL; p<0.0001), sign

2 those assigned emtricitabine plus tenofovir disoproxil fumarate (0.48 cases per 100 person-years); H

3 mg) twice daily and emtricitabine/tenofovir disoproxil fumarate (200/300 mg) once daily.

4 ed (1:1) to receive daily combined tenofovir disoproxil fumarate (245 mg) and emtricitabine (200 mg)

5 were given combination tablets of tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg)

6 5 mg), emtricitabine (200 mg), and tenofovir disoproxil fumarate (300 mg), with matching placebo, onc

7 0 mg), emtricitabine (200 mg), and tenofovir disoproxil fumarate (300 mg), with matching placebo.

8 ach additional year of exposure to tenofovir disoproxil fumarate (adjusted incidence rate ratio 1.14

9 ir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (combined ART).

10 ), or efavirenz plus emtricitabine-tenofovir-disoproxil fumarate (DF) (EFV+FTC-TDF).

11 ntrolled intensification trials of tenofovir disoproxil fumarate (DF) in treatment-experienced human

12 Tenofovir disoproxil fumarate (DF) is a once-daily nucleotide anal

13 Tenofovir disoproxil fumarate (DF) is highly effective for the sup

14 s were randomized 1:1:1 to receive tenofovir-disoproxil fumarate (DF) plus emtricitabine, and either

15 ned to receive either a regimen of tenofovir disoproxil fumarate (DF), emtricitabine, and efavirenz o

16 combination therapy with efavirenz-tenofovir disoproxil fumarate (DF)-emtricitabine once daily (EFV-T

17 infection: abacavir-lamivudine or tenofovir disoproxil fumarate (DF)-emtricitabine plus efavirenz or

18 -controlled abacavir-lamivudine or tenofovir disoproxil fumarate (DF)-emtricitabine.

19 als received oral topical doses of tenofovir disoproxil fumarate (DF; equivalent to 0.037 mg of tenof

20 30 (93%) of 140 patients receiving tenofovir disoproxil fumarate (difference 1.8% [95% CI -3.6 to 7.2

21 F/tenofovir alafenamide) or 300 mg tenofovir disoproxil fumarate (E/C/F/tenofovir disoproxil fumarate

22 th that of efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF).

23 itegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/c/FTC/TDF) with that of efavire

24 TDF) and combination emtricitabine/tenofovir disoproxil fumarate (FTC+TDF), is efficacious for preven

25 etroviral drugs, emtricitabine and tenofovir disoproxil fumarate (FTC-TDF), or placebo once daily.

26 combination oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) as preexposure prophylaxis

27 (PrEP) with oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) decreases the risk of huma

28 phylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) is a novel strategy for pr

29 n the United States, emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) is a preferred nucleoside

30 xis (PrEP) with emtricitabine plus tenofovir disoproxil fumarate (FTC/TDF) or TDF alone reduces the r

31 % tenofovir (TFV) and oral emtricitabine/TFV disoproxil fumarate (FTC/TDF).

32 neral density than those receiving tenofovir disoproxil fumarate (hip -0.29% [95% CI -0.55 to -0.03]

33 1 occurred in individuals assigned tenofovir disoproxil fumarate (incidence 0.71 cases per 100 person

34 ir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (integrase inhibitor regimen) or rit

35 67 to 200 mg, and 66 to 400 mg) or tenofovir disoproxil fumarate (n=101).

36 r tenofovir alafenamide (n=333) or tenofovir disoproxil fumarate (n=330).

37 avirenz and lamivudine plus either tenofovir disoproxil fumarate (n=55) or stavudine (n=45), by use o

38 atazanavir with emtricitabine and tenofovir disoproxil fumarate (protease inhibitor based regimen);

39 ustment, persons who had ever used tenofovir disoproxil fumarate (TDF) (1.40; 1.15-1.70) or who were

40 is (PrEP) using the antiretroviral tenofovir disoproxil fumarate (TDF) alone or in combination with e

41 Tenofovir disoproxil fumarate (TDF) and adefovir dipivoxil (ADV) a

42 exposure prophylaxis (PrEP), using tenofovir disoproxil fumarate (TDF) and combination emtricitabine/

43 RTI) based FDC of rilpivirine plus tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) (Compl

44 assigned to take a combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) or pla

45 GROUND & AIMS: Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are potent antiviral agents th

46 bine (FTC), rilpivirine (RPV), and tenofovir disoproxil fumarate (TDF) as a 3-drug, single-tablet reg

47 HIV and HBV who were treated with tenofovir disoproxil fumarate (TDF) as part of highly active antir

48 apy currently receive some form of tenofovir disoproxil fumarate (TDF) as part of their HIV treatment

49 PrEP) with emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) can partially prevent rectal H

50 hat delivers the tenofovir prodrug tenofovir disoproxil fumarate (TDF) continuously over 28 d.

51 The approved tenofovir disoproxil fumarate (TDF) dose of 300 mg every 48 hours

52 Tenofovir disoproxil fumarate (TDF) has been linked to renal impai

53 t (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) in a single tablet given once

54 ntigen positive patients receiving tenofovir disoproxil fumarate (TDF) in an open-label, longterm ext

55 We examined the efficacy of tenofovir disoproxil fumarate (TDF) in blocking simian human immun

56 Despite widespread use of tenofovir disoproxil fumarate (TDF) in pregnant and breastfeeding

57 he efficacy and safety of maternal tenofovir disoproxil fumarate (TDF) in reducing mother-to-infant h

58 mbination with emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in treatment-naive patients.

59 t (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) into a once-daily, single tabl

60 Tenofovir disoproxil fumarate (TDF) is a nucleotide analog with ex

61 Tenofovir disoproxil fumarate (TDF) is a nucleotide analogue with

62 Tenofovir disoproxil fumarate (TDF) is active against lamivudine-r

63 Tenofovir disoproxil fumarate (TDF) is an established nucleotide a

64 Tenofovir disoproxil fumarate (TDF) is associated with proximal tu

65 Tenofovir disoproxil fumarate (TDF) is commonly used in antiretrov

66 Exposure to tenofovir disoproxil fumarate (TDF) may cause renal toxicity.

67 Tenofovir disoproxil fumarate (TDF) plays a pivotal role in antire

68 Clinical studies of systemic tenofovir disoproxil fumarate (TDF) PrEP revealed reduced efficacy

69 nts with rapid or slow response to tenofovir disoproxil fumarate (TDF) treatment, have been examined

70 og10 copies/mL, after 240 weeks of tenofovir disoproxil fumarate (TDF) treatment.

71 Although tenofovir disoproxil fumarate (TDF) use has increased as part of f

72 ong patients receiving LDV/SOF and tenofovir disoproxil fumarate (TDF) without a protease inhibitor (

73 Some studies have shown that tenofovir disoproxil fumarate (TDF), a drug widely used in highly

74 Once-daily oral tenofovir disoproxil fumarate (TDF), alone or combined with emtric

75 plus emtricitabine (FTC), MVC plus tenofovir disoproxil fumarate (TDF), and TDF plus FTC.

76 only, MVC-emtricitabine (FTC), MVC-tenofovir disoproxil fumarate (TDF), and TDF-FTC (control).

77 bout 50-fold higher than those seen with TFV disoproxil fumarate (TDF), and they remained above 1,000

78 184V/I (0.1%), despite high use of tenofovir disoproxil fumarate (TDF), emtricitabine, and lamivudine

79 fovir and a potential successor of tenofovir disoproxil fumarate (TDF), has been approved in the Unit

80 o assess daily treatment with oral tenofovir disoproxil fumarate (TDF), oral tenofovir-emtricitabine

81 Tenofovir disoproxil fumarate (TDF), the first nucleotidic inhibit

82 strate that a novel gel containing tenofovir disoproxil fumarate (TDF), the more potent prodrug of te

83 (PrEP) with a novel gel containing tenofovir disoproxil fumarate (TDF), the tenofovir prodrug, but no

84 It is unknown if tenofovir disoproxil fumarate (TDF), which is often coformulated w

85 We compared maraviroc (MVC)- to tenofovir disoproxil fumarate (TDF)-containing ART.

86 of renal and endocrine changes in tenofovir disoproxil fumarate (TDF)-related bone toxicity.

87 We hypothesized that tenofovir disoproxil fumarate (TDF)-treated patients taking PI/r-b

88 troviral therapy (cART) containing tenofovir disoproxil fumarate (TDF).

89 e clinically approved formulation, tenofovir disoproxil fumarate (TDF).

90 ficacy of oral emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF).

91 ymptomatic HSV-2 infection to oral tenofovir disoproxil fumarate (TDF)/placebo vaginal gel, oral plac

92 signed to groups given either oral tenofovir disoproxil fumarate (TDF, 300 mg) and placebo (n = 64) o

93 Tenofovir disoproxil fumarate (tenofovir) has been associated with

94 ir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (tenofovir) might be a safe and effi

95 e inhibitor and emtricitabine plus tenofovir disoproxil fumarate (tenofovir) regimen to coformulated

96 .01 mg/dL [95% CI 0.00 to 0.02] vs tenofovir disoproxil fumarate 0.02 mg/dL [0.00 to 0.04], adjusted

97 r alafenamide 40 [14%] patients vs tenofovir disoproxil fumarate 14 [10%] patients), nasopharyngitis

98 or 400 mg once a day or to receive tenofovir disoproxil fumarate 300 mg once a day; each allocation w

99 of tenofovir alafenamide 25 mg or tenofovir disoproxil fumarate 300 mg, each with matching placebo.

100 r (RTV) or standard of care (SOC) (tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, and AT

101 h Truvada (emtricitabine [FTC] and tenofovir disoproxil fumarate [TDF]) is a novel HIV prevention str

102 gnificantly different from that of tenofovir disoproxil fumarate alone (hazard ratio [HR] 0.67, 95% C

103 ficacy of daily oral emtricitabine-tenofovir disoproxil fumarate among HIV-seronegative men and trans

104 Daily, oral use of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) for pree

105 ve men and women to receive either tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) or match

106 to receive either a combination of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) or place

107 reexposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine (Truvada) has demo

108 e-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine for the prevention

109 sure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine in 2499 men who ha

110 osted atazanavir plus coformulated tenofovir disoproxil fumarate and emtricitabine once a day (atazan

111 ir/ritonavir and 2 nucleos(t)ides (tenofovir disoproxil fumarate and emtricitabine or abacavir and la

112 let) orally twice daily, each with tenofovir disoproxil fumarate and emtricitabine orally once daily,

113 -group phase 3 trial of daily oral tenofovir disoproxil fumarate and emtricitabine plus tenofovir dis

114 earance and the number of doses of tenofovir disoproxil fumarate and emtricitabine taken per week, as

115 ts started RAL in combination with tenofovir disoproxil fumarate and lamivudine after initiation of R

116 01 had similar efficacy to that of tenofovir disoproxil fumarate and was associated with a smaller de

117 xil fumarate or emtricitabine plus tenofovir disoproxil fumarate and were followed up for HIV-1 acqui

118 genotypes for nonresponders in the tenofovir disoproxil fumarate arm showed M184V or I/M/V mixtures i

119 in 50 (49%) of 102 subjects in the tenofovir disoproxil fumarate arm, compared with 5 (5%) of 92 of s

120 immediately amended to modify the tenofovir disoproxil fumarate arm.

121 to combination emtricitabine plus tenofovir disoproxil fumarate as PrEP.

122 xil fumarate or emtricitabine plus tenofovir disoproxil fumarate as PrEP.

123 target cells more efficiently than tenofovir disoproxil fumarate at a lower dose, thereby reducing sy

124 oral PrEP with emtricitabine plus tenofovir disoproxil fumarate at a research centre in Cape Town, S

125 Tenofovir disoproxil fumarate can cause renal and bone toxic effec

126 ir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate compared with a boosted protease inh

127 ifference in HIV-1 protection with tenofovir disoproxil fumarate compared with emtricitabine plus ten

128 PrEP with oral emtricitabine plus tenofovir disoproxil fumarate compared with placebo in men who hav

129 fumarate; one patient assigned to tenofovir disoproxil fumarate did not receive the treatment.

130 ide and 12 (4%) patients receiving tenofovir disoproxil fumarate experienced serious adverse events,

131 ad been on daily emtricitabine and tenofovir disoproxil fumarate for 8 months presented with fever, u

132 ) on efavirenz, emtricitabine, and tenofovir disoproxil fumarate for at least 6 months before enrolme

133 on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate for at least 6 months before enrolme

134 and 93% for the emtricitabine plus tenofovir disoproxil fumarate group (0.07, 0.02-0.23; p<0.0001).

135 p and in 444 (93%) assigned to the tenofovir disoproxil fumarate group (adjusted difference 4.1%, 95%

136 oup compared with 307 (93%) in the tenofovir disoproxil fumarate group (difference 1.3%, 95% CI -2.5

137 ction in HIV-1 acquisition for the tenofovir disoproxil fumarate group (HR 0.15, 95% CI 0.06-0.37; p<

138 ompared with 88 (89%) of 99 in the tenofovir disoproxil fumarate group (modified intention-to-treat p

139 tudy treatment; one patient in the tenofovir disoproxil fumarate group died, but this was not deemed

140 enamide (2%) and three (1%) in the tenofovir disoproxil fumarate group discontinued due to adverse ev

141 nd 96 (33%) of 292 patients in the tenofovir disoproxil fumarate group had grade 3 or 4 laboratory ab

142 d thrombocytopenia) and two in the tenofovir disoproxil fumarate group had study drug-related serious

143 d 784 (90%) of 867 patients in the tenofovir disoproxil fumarate group having plasma HIV-1 RNA less t

144 oxil fumarate-containing regimens (tenofovir disoproxil fumarate group) for 96 weeks.

145 r alafenamide group and 314 to the tenofovir disoproxil fumarate group).

146 the efavirenz, emtricitabine, and tenofovir disoproxil fumarate group.

147 r alafenamide group and 477 to the tenofovir disoproxil fumarate group.

148 e group compared with those in the tenofovir disoproxil fumarate group.

149 mpared with 37 (12%) of 314 in the tenofovir disoproxil fumarate group; none of these were serious.

150 lafenamide and 294 (94%) of 313 on tenofovir disoproxil fumarate had maintained less than 50 copies p

151 e and nine (6%) patients receiving tenofovir disoproxil fumarate had serious adverse events, none of

152 C/F/tenofovir alafenamide or E/C/F/tenofovir disoproxil fumarate had virological success.

153 Antiretroviral regimens containing tenofovir disoproxil fumarate have been associated with renal toxi

154 l tenofovir disoproxil fumarate or tenofovir disoproxil fumarate in combination with emtricitabine, h

155 inuing rilpivirine, emtricitabine, tenofovir disoproxil fumarate in maintaining viral suppression and

156 cy and safety of BMS-986001 versus tenofovir disoproxil fumarate in treatment-naive patients with HIV

157 PrEP with oral emtricitabine plus tenofovir disoproxil fumarate in women.

158 Emtricitabine with tenofovir disoproxil fumarate is a standard-of-care nucleoside rev

159 However, tenofovir disoproxil fumarate is associated with renal and bone to

160 axis (PrEP) with emtricitabine and tenofovir disoproxil fumarate is highly effective against acquisit

161 Daily emtricitabine/tenofovir disoproxil fumarate is recommended as preexposure prophy

162 (PrEP) with oral emtricitabine and tenofovir disoproxil fumarate is used to prevent the sexual acquis

163 tegravir twice daily and 300 mg of tenofovir disoproxil fumarate once daily as a backbone.

164 12 among patients receiving either tenofovir disoproxil fumarate or abacavir as part of their antiret

165 followed; adjustment should avoid tenofovir disoproxil fumarate or boosted protease inhibitors in at

166 rerandomisation in a 1:1 ratio to tenofovir disoproxil fumarate or emtricitabine plus tenofovir diso

167 0 (99.6%) of 4427 couples received tenofovir disoproxil fumarate or emtricitabine plus tenofovir diso

168 ate, but show that once-daily oral tenofovir disoproxil fumarate or emtricitabine plus tenofovir diso

169 antiretroviral regimens containing tenofovir disoproxil fumarate or other nucleoside analog RT drugs.

170 rophylaxis (PrEP), with daily oral tenofovir disoproxil fumarate or tenofovir disoproxil fumarate in

171 EC, n = 293), and C (emtricitabine-tenofovir-disoproxil fumarate plus efavirenz, n = 278) as part of

172 rEP), using daily oral combination tenofovir disoproxil fumarate plus emtricitabine, is an effective

173 xposure by the third daily dose of tenofovir disoproxil fumarate plus emtricitabine.

174 study of daily oral emtricitabine-tenofovir disoproxil fumarate PrEP among 50 HIV-uninfected breastf

175 il fumarate and emtricitabine plus tenofovir disoproxil fumarate PrEP in HIV-1 uninfected individuals

176 d 402 (92%) of 437 assigned to the tenofovir disoproxil fumarate regimen (difference -2.0%, 95.001% C

177 dose of study drug and were on the tenofovir disoproxil fumarate regimen before screening were includ

178 xil fumarate or emtricitabine plus tenofovir disoproxil fumarate regimens both provide high protectio

179 essed the efficacy of single-agent tenofovir disoproxil fumarate relative to combination emtricitabin

180 switching from emtricitabine with tenofovir disoproxil fumarate to emtricitabine with tenofovir alaf

181 were independent of emtricitabine/tenofovir disoproxil fumarate use.

182 , open-label, multicenter study of tenofovir disoproxil fumarate versus efavirenz, both administered

183 aining regimen from one containing tenofovir disoproxil fumarate was non-inferior for maintenance of

184 from efavirenz, emtricitabine, and tenofovir disoproxil fumarate was non-inferior in maintaining vira

185 n efficacy with emtricitabine plus tenofovir disoproxil fumarate was not significantly different from

186 he 195 (67%) of patients receiving tenofovir disoproxil fumarate who had HBV DNA less than 29 IU/mL (

187 mg tenofovir alafenamide or 300 mg tenofovir disoproxil fumarate with matching placebo.

188 36 [13%] of 288 patients receiving tenofovir disoproxil fumarate) and AST (20 [3%] of 577 patients re

189 on cART (predominantly containing tenofovir disoproxil fumarate) were also more likely to experience

190 nofovir disoproxil fumarate (E/C/F/tenofovir disoproxil fumarate) with matching placebo.

191 22 [8%] of 292 patients receiving tenofovir disoproxil fumarate), nasopharyngitis (56 [10%] vs 16 [5

192 ir alafenamide and 867 given E/C/F/tenofovir disoproxil fumarate).

193 437 with efavirenz, emtricitabine, tenofovir disoproxil fumarate).

194 regimens include emtricitabine and tenofovir disoproxil fumarate).

195 tenofovir alafenamide and 292 with tenofovir disoproxil fumarate).

196 19 [7%] of 288 patients receiving tenofovir disoproxil fumarate).

197 ation emtricitabine, 200 mg/d, and tenofovir disoproxil fumarate, 300 mg/d.

198 as a vaginal gel or as daily oral tenofovir disoproxil fumarate, alone or coformulated with emtricit

199 olites of abacavir, emtricitabine, tenofovir disoproxil fumarate, amdoxovir, and zidovudine, as well

200 ART-naive patients received RAL, tenofovir disoproxil fumarate, and emtricitabine for 72 weeks.

201 namide was non-inferior to that of tenofovir disoproxil fumarate, and had improved bone and renal eff

202 ir alafenamide was non-inferior to tenofovir disoproxil fumarate, and had improved bone and renal eff

203 of lopinavir/ritonavir, efavirenz, tenofovir disoproxil fumarate, and lamivudine and compared it with

204 than a standard regimen containing tenofovir disoproxil fumarate, and might be a treatment option for

205 e compared with emtricitabine plus tenofovir disoproxil fumarate, but show that once-daily oral tenof

206 infants exposed from conception to tenofovir disoproxil fumarate, emtricitabine, and efavirenz (TDF-F

207 Newer agents including tenofovir disoproxil fumarate, entecavir, and telbivudine offer gr

208 Compared with tenofovir disoproxil fumarate, individuals in the BMS-986001 group

209 one (1%) of 99 patients receiving tenofovir disoproxil fumarate, respectively.

210 d for up to 6 years of exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazanavir, or ri

211 ciated with cumulative exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazanavir, riton

212 ues were treated with a regimen of tenofovir disoproxil fumarate, saquinavir, atazanavir, and an inte

213 Tenofovir disoproxil fumarate, the most recently approved nucleoti

214 oncentrations by 90% compared with tenofovir disoproxil fumarate, thereby decreasing bone and renal r

215 e efficiently at a lower dose than tenofovir disoproxil fumarate, thereby reducing systemic exposure.

216 ens, each for 6 weeks (oral 300 mg tenofovir disoproxil fumarate, vaginal 1% tenofovir gel [40 mg], o

217 mtricitabine with 200 mg or 300 mg tenofovir disoproxil fumarate, while remaining on the same third a

218 fenamide was non-inferior to E/C/F/tenofovir disoproxil fumarate, with 800 (92%) of 866 patients in t

219 alafenamide was as efficacious as tenofovir disoproxil fumarate, with reduced bone and renal toxic e

220 to HIV-negative individuals using tenofovir disoproxil fumarate-based pre-exposure prophylaxis for t

221 arly all (97.6%) patients received tenofovir disoproxil fumarate-containing ART, in line with nationa

222 rry on taking one of four previous tenofovir disoproxil fumarate-containing regimens (tenofovir disop

223 eater, and were taking one of four tenofovir disoproxil fumarate-containing regimens for at least 96

224 enal and bone safety compared with tenofovir disoproxil fumarate-containing regimens.

225 cipants were randomized to receive tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) plus atazana

226 onsistent use of emtricitabine and tenofovir disoproxil fumarate.

227 enal and bone safety compared with tenofovir disoproxil fumarate.

228 s switched from emtricitabine with tenofovir disoproxil fumarate.

229 tiation of efavirenz/emtricitabine/tenofovir disoproxil fumarate.

230 iority of tenofovir alafenamide to tenofovir disoproxil fumarate.

231 ease inhibitor, emtricitabine, and tenofovir disoproxil fumarate.

232 on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate.

233 atazanavir with emtricitabine and tenofovir disoproxil fumarate.

234 those remaining on one containing tenofovir disoproxil fumarate.

235 ated efavirenz, emtricitabine, and tenofovir disoproxil fumarate.

236 enofovir alafenamide compared with tenofovir disoproxil fumarate.

237 The tenofovir disoproxil fumarate/abacavir/lamivudine regimen resulted

238 tudy estimated the number of daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) doses requir

239 PrEP) interventions worldwide, yet tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for PrEP is

240 individuals randomized equally to tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) plus atazana

241 virologically suppressed on tenofovir (TFV) disoproxil fumarate/emtricitabine and ritonavir-boosted

242 Daily tenofovir disoproxil fumarate/emtricitabine is recommended for use

243 ted with suboptimal adherence, and tenofovir disoproxil fumarate/emtricitabine was associated with hi

244 ors (NRTIs; abacavir/lamivudine or tenofovir disoproxil fumarate/emtricitabine) and a third single or

245 ir alafenamide and 141 assigned to tenofovir disoproxil fumarate; one patient assigned to tenofovir d

246 ed regimen of background N(t)RTIs (tenofovir-disoproxil-fumarate plus emtricitabine, zidovudine plus

247 ose combination emtricitabine with tenofovir disoproxil fumartate from 78 sites in North America and